A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

Clinical trial NCT05231785 · RECRUITING

Trial details

NCT number: NCT05231785
Sponsor: Alnylam Pharmaceuticals
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Early-Onset Alzheimer Disease

Start date: 2022-02-04
Primary completion: 2029-04-20
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.